Late stage pipeline
Focus on Innovation and Science to unlock mid-term potential
Pipeline updated as of March 2023
|
Molecule /
Project
|
Indication
|
Expected Launch
|
Preclinical Phase | Phase I | Phase II | Phase III | Under Registration | Geography |
|---|---|---|---|---|---|---|---|---|
| Efinaconazole | Onychomycosis |
2024
|
EU
|
|||||
| Sarecycline | Acne |
2024
|
China
|
|||||
|
Tribanibulin LF |
Actinic keratosis |
EU 2026
|
EU
|
|||||
|
ALM223 Early stage |
Autoimmune dermatology |
TBD
|
|
|||||
| ALM401 | Autoimmune dermatology |
TBD
|
|
|||||
| ALM27134 | Autoimmune dermatology |
TBD
|
|
* Worldwide ex-Greater China